Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2019-05-15 Earnings Release
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon AG: Formycon Reports Successful 2018 Financial Year
Earnings Release Classification · 100% confidence The document is titled "Formycon AG: Formycon Reports Successful 2018 Financial Year" and explicitly states, "Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today published its 2018 Annual Report...". It contains detailed financial highlights (turnover, EBITDA, equity ratio) for the 2018 financial year, which is characteristic of an Annual Report or an Earnings Release. However, the content is a press release summarizing the results and announcing the publication of the full 2018 Annual Report, which is linked at the end. Since it provides the key financial highlights and is explicitly an announcement of the full annual results, it aligns best with an Earnings Release (ER). If the document were the full 10-K filing itself, it would be much longer and structured differently. Given the focus on summarizing the '2018 Financial Year' results immediately, ER is the most appropriate classification for this summary announcement, rather than the full 10-K or just an RPA (which usually just announces the availability without summarizing key figures). FY 2018
2019-05-15 English
Annual financial statements 2018
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2018' and contains comprehensive sections including a letter to shareholders from the CEO/CFO, a report from the Supervisory Board, and a detailed Management Report table of contents. It covers the company's business performance, financial outlook, and strategic initiatives for the fiscal year 2018. It meets the criteria for a full Annual Report (10-K equivalent for non-US entities). FY 2018
2019-05-15 German
Formycon AG: Formycon Announces News on Development Portfolio
Regulatory Filings Classification · 99% confidence The document is titled 'Formycon Announces News on Development Portfolio' and is explicitly labeled as a 'Press Release' published via DGAP-News. It details updates on drug development candidates (FYB201, FYB202, FYB203), regulatory milestones (FDA/EMA submissions), preclinical study results, and legal changes affecting the industry. This content is an announcement providing key operational and pipeline updates, rather than a comprehensive annual report (10-K), a formal earnings release (ER), or a transcript (CT). Since it is a general corporate news announcement detailing operational progress and strategy updates, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a broad disclosure disseminated through a regulatory news service (DGAP), or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate catch-all for significant, non-standard disclosures.
2019-05-13 English
Formycon AG: Strategic Investor M&H Equity AG Subscribes Cash Capital Increase of Euro 17.3 Million
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated March 26, 2019, announcing that a strategic investor (M&H Equity AG) subscribed to a cash capital increase of EUR 17.3 Million by subscribing to 577,397 new bearer shares. This action directly relates to the company's capital structure and fundraising activities. This fits the definition of 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2019-03-26 English
Formycon AG: Formycon Releases Updates on Development Programs and Milestones
Regulatory Filings Classification · 99% confidence The document is titled 'Formycon Releases Updates on Development Programs and Milestones' and is explicitly labeled as a 'Press Release' disseminated via DGAP-News. It provides updates on clinical trial progress (Phase III completion, data availability), regulatory interactions (FDA/EMA meetings), and future development plans for several biosimilar candidates (FYB201, FYB202, FYB203). This content is characteristic of an announcement detailing operational and scientific progress, rather than a formal regulatory filing like a 10-K, an official earnings release (ER), or a comprehensive quarterly report (IR). Since it is a press release announcing operational updates and milestones, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, although it is more specific than a typical RNS filing. Given the options, it is a general corporate news release about study results and development progress, which often falls under RNS if no other specific category like ER or IR applies. It is not a report itself, nor a proxy statement, nor a management discussion, but a news update.
2018-11-20 English
Datum:19.11.2018
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) and 'Lagebericht' (Management Report) for Formycon AG for the fiscal year 2017. It contains detailed financial data, business model descriptions, research and development activities, and management commentary. As it covers the full fiscal year and provides comprehensive financial performance, it is classified as an Annual Report (10-K). FY 2017
2018-11-19 German

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.